COPART INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CPRT in the last 7 days.
No SEC Form 4 filings for $CPRT in the last 30 days.
See all $CPRT insider activity →Copart Inc. (CPRT) extended its tender offer for ACV Auctions Inc. (ACVA) to October 7, 2026, offering $10.50 per share. The extension follows a refiling under the HSR Act. As of Tuesday, 81.27 million shares, or 47.78% of outstanding shares, were tendered. The offer requires over 50% of shares to be tendered and HSR Act approval.
Copart Inc. (CPRT) reported $4.67B in revenue for FY2026, with a net income of $1.48B and a 32% net income margin. The company's GF Score is 85/100, and its GF Value is $57.08, suggesting undervaluation at $27.14. Strengths include high profitability, innovative tech, and global reach, while weaknesses include high operating expenses and insider selling. Opportunities lie in online auctions, emerging markets, and EVs, with threats from competition, economic downturns, and regulations.
Copart refiled its US antitrust notification for its $1.9 billion acquisition of ACV Auctions, setting an Oct. 13 deadline for regulators' initial review. This step follows the withdrawal and resubmission of the paperwork.
Recent CPRT coverage spans financial news, mergers & acquisitions and corporate actions.
Extension may dampen short-term momentum in CPRT as the deal timeline is pushed back.
No fresh catalyst; the piece is a retrospective analysis of already‑public financials.
The refiling may delay closure and introduce regulatory risk, pressuring Copart's share price.
The tranche update confirms the buyback program is finished with no new activity, likely limiting any immediate price impact.
The numbers have been public for weeks, so the market has likely already priced them in.
AlphAI scores every news story that mentions CPRT with an AI model for sentiment and relevance, and aggregates insider trades from COPART INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Copart Inc. (CPRT) extended its tender offer for ACV Auctions Inc. (ACVA) to October 7, 2026, offering $10.50 per share. The extension follows a refiling under the HSR Act. As of Tuesday, 81.27 million shares, or 47.78% of outstanding shares, were tendered. The offer requires over 50% of shares to be tendered and HSR Act approval.
2 min readCopart Inc. (CPRT) reported $4.67B in revenue for FY2026, with a net income of $1.48B and a 32% net income margin. The company's GF Score is 85/100, and its GF Value is $57.08, suggesting undervaluation at $27.14. Strengths include high profitability, innovative tech, and global reach, while weaknesses include high operating expenses and insider selling. Opportunities lie in online auctions, emerging markets, and EVs, with threats from competition, economic downturns, and regulations.
3 min readCopart refiled its US antitrust notification for its $1.9 billion acquisition of ACV Auctions, setting an Oct. 13 deadline for regulators' initial review. This step follows the withdrawal and resubmission of the paperwork.
1 min readCopart Inc. (CPRT) reported no share repurchases in the latest tranche (May 1, 2026 to July 31, 2026). The company has completed 37.77% of its buyback plan, repurchasing 501,629,956 shares for $3.02 billion since February 20, 2003, according to the update.
1 min readCOPART INC reported FY 2026 revenue of $4.67B, flat year-over-year, and net income of $1.41B, maintaining a 32% margin. Service revenues were stable at $3.97B, with international growth offsetting U.S. declines. The company opened 25 new facilities and agreed to acquire ACV for $1.9B to expand remarketing capabilities.
1 min readAnalysts updated price targets for several companies. UBS raised Vertex's (VRTX) target to $615, Melius cut McDonald's (MCD) to $230, and Piper Sandler increased Alphabet's (GOOGL) target to $400. Other notable changes include Okta (OKTA), AutoZone (AZO), Vaxcyte (PCVX), Camping World (CWH), Copart (CPRT), Delta (DAL), and Fiserv (FISV).
2 min readBNP Paribas reiterated its 'Outperform' rating for Copart (CPRT) and raised its price target to $43.00, up from $40.00. The firm cited confidence in Copart's business model and market position. GuruFocus values the stock at $57.07, suggesting a 52% undervaluation. Copart has a GF Score of 85/100, indicating strong financial performance.
2 min readBNP Paribas raised its price target for Copart from $40 to $43. The stock has seen a 5-day change of 27.59 USD, a 1st Jan change of -1.60%, and a year-to-date change of -5.77%. The adjustment reflects the bank's updated outlook on the company's valuation and earnings potential.
1 min readThe Tuttle Capital Heavy Assets Low Obsolescence Index (HALX) was rebalanced, adding AutoZone, United Therapeutics, and others, while removing SpaceX and four other companies. The index focuses on firms with heavy assets and low AI disruption risk, potentially benefiting investors concerned about AI's impact.
2 min readAnalysts updated ratings for five stocks: Rocket Pharmaceuticals (RCKT) was upgraded to Buy with a $9 target due to FDA confidence in its Danon disease study. Copart (CPRT) was downgraded to Hold with a $36 target due to weak insurance volumes and rising costs. Pegasystems (PEGA) was downgraded to Neutral with a $47 target due to AI-related disruption. Abeona Therapeutics (ABEO) was initiated with a Buy and $17 target due to strong gene therapy prospects. Fluence Energy (FLNC) was downgraded to
2 min read
